Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eylea Pre-Filled Syringe Now Available in Japan: Bayer, Santen
June 8, 2020
- Nipro Launches Stemirac Manufacturing Facility in Tokyo
June 8, 2020
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- Opdivo Top-Selling Drug in May, Keytruda Falls to Second: Encise
June 5, 2020
- Kyowa Kirin Looks to Make Crysvita 1st In-House Blockbuster, Sees 100 Billion Yen Target “Not Unachievable”
June 5, 2020
- Humira Remains Global Top-Seller in 2019
June 4, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
- Shionogi Aims at 500 Billion Yen Sales in FY2024: New 5-Year Plan
June 3, 2020
- Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
- Asahi Kasei Pharma Grabs China Approval for Flivas
June 3, 2020
- Eisai’s Insomnia Med Dayvigo Now Available in US
June 3, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Torii, ASKA to Copromote Riona for Iron Deficiency Anemia
June 2, 2020
- 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
- Onivyde Now Available in Japan: Servier/Yakult
June 2, 2020
- Daiichi Sankyo to Test TROP2-Directed ADC plus Keytruda in NSCLC
June 2, 2020
- Takeda Launching Project to Gauge Parkinson’s Symptoms with Wearables, Telemedicine Platform
June 2, 2020
- Takeda Gets CHMP Backing for Takhzyro Pre-Filled Syringe
June 2, 2020
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…